Data presented at the American Diabetes Association's 80th Scientific Sessions – June 12-16
Company | Product | Description | Indication | Status | Date |
Hua Medicine Ltd., of Shanghai | Dorzagliatin | Glucokinase stimulator | Type 2 diabetes | In phase III Seed monotherapy study, beta-cell function improved, with increase of 2.56% in HOMA2-beta for study drug vs. decline of 0.72% for placebo; dorzagliatin also achieved statistically significant reduction of 1.07% from baseline in HbA1c | 6/15/20 |
Notes The date indicated refers to the BioWorld table in which the news item can be found. For more information about individual companies and/or products, see Cortellis. |
Data presented at the American Academy of Dermatology's annual meeting – June 12-14
Company | Product | Description | Indication | Status | Date |
Brickell Biotech Inc., of Boulder, Colo., and Kaken Pharmaceutical Co. Ltd., of Tokyo | Sofpironium bromide gel | Blocks acetylcholine | Primary axillary hyperhidrosis | In the phase III study, 53.9% of patients taking the drug had a response, defined as a score of 1 or 2 on the Hyperhidrosis Disease Severity Scale and at least a 50% reduction in gravimetric sweat production, compared to 36.4% of patient treated with vehicle (p=0.003); drug changed HDSM-Ax score by -1.41 vs. -0.93 for vehicle (p=0.001) | 6/15/20 |
Notes The date indicated refers to the BioWorld table in which the news item can be found. For more information about individual companies and/or products, see Cortellis. |